Acasti Pharma's Hemorrhage Candidate Shows Encouraging PK Profile In Healthy VolunteersBenzinga • 12/02/21
Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104GlobeNewsWire • 12/02/21
Acasti Pharma CEO to Participate in the Benzinga All Access Event on December 2ndGlobeNewsWire • 11/24/21
Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earning Call TranscriptSeeking Alpha • 11/10/21
Acasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference CallGlobeNewsWire • 11/04/21
Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in JapanGlobeNewsWire • 10/06/21
Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company's Lead Drug Candidate for the Treatment of Subarachnoid HemorrhageGlobeNewsWire • 09/27/21
Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing StandardsGlobeNewsWire • 09/22/21
Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21ˢᵗGlobeNewsWire • 09/14/21
Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock SplitGlobeNewsWire • 08/27/21
Reminder: Acasti Pharma to Host Conference Call on August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace TherapeuticsGlobeNewsWire • 07/29/21
Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace TherapeuticsGlobeNewsWire • 07/23/21